Campath Overdose, Contraindications and Information - Alemtuzumab

Campath Overdose, Contraindications and Information - Alemtuzumab

OVERDOSE

Initial doses of Campath of greater than 3 mg are not well-tolerated. One patient who received 80 mg as an initial dose by IV infusion experienced acute bronchospasm, cough, and shortness of breath, followed by anuria and death. A review of the case suggested that tumor lysis syndrome may have played a role.

Single doses of Campath greater than 30 mg or a cumulative weekly dose greater than 90 mg should not be administered as higher doses have been associated with a higher incidence of pancytopenia. (See BOXED WARNING and DOSAGE AND ADMINISTRATION.)

There is no known specific antidote for Campath overdosage. Treatment consists of drug discontinuation and supportive therapy.

Campath is contraindicated in patients who have active systemic infections, underlying immunodeficiency (e.g.,seropositive for HIV),or known Type I hypersensitivity or anaphylactic reactions to Campath or to any one of its components.